Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE

NCT04316117 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT04316117
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04316117 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 15, 2020
Completion date
August 31, 2027
Enrollment
138 (actual)
Sites
104

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage iv breast cancer ajcc v8, hormone receptor positive breast carcinoma, metastatic breast carcinoma, prognostic stage iv breast cancer ajcc v8